Takatsuki, Japan

Yoshiaki Okada

This inventor holds 1 USPTO granted patent. Top assignee: Daiichi Radioisotope Laboratories, Ltd.. Active years: 1981.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yoshiaki Okada. Retrieved from https://idiyas.com/inventor/yoshiaki-okada-gc23wb3i

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 1981

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yoshiaki Okada: Innovator in Radioimmunoassay Technology

Introduction

Yoshiaki Okada is a notable inventor based in Takatsuki, Japan. He has made significant contributions to the field of medical diagnostics, particularly through his innovative work in radioimmunoassay methods.

Latest Patents

Yoshiaki Okada holds a patent for a radioimmunoassay method for determining calcitonin. This method utilizes a radioactive labeled hentriacontapeptide, which is essential for accurate measurement in clinical settings.

Career Highlights

Okada is associated with Daiichi Radioisotope Laboratories, Ltd., where he has been instrumental in advancing research and development in radioimmunoassay technologies. His work has paved the way for improved diagnostic techniques in medicine.

Collaborations

He has collaborated with notable colleagues, including Shoichiro Tsushima and Hiroshi Ogawa, contributing to the advancement of their shared field of expertise.

Conclusion

Yoshiaki Okada's innovative contributions to radioimmunoassay methods highlight his importance in the medical diagnostics field. His work continues to influence advancements in healthcare technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…